Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions

Saudi Pharmaceutical Journal

Volumn 24, Issue 4, 2016, Pages 485-493

  Khan, Lateef M ^a   Al Harthi, Sameer E ^a   Osman, Abdel Moneim M ^a,b   Sattar, Mai A Alim A ^a,c   Ali, Ahmed S ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Adverse drug reactions; Algorithms; Causality assessment tools; Pharmacovigilance

Indexed keywords

ANTIINFECTIVE AGENT; VALPROIC ACID;

ADVERSE DRUG REACTION; CAUSAL ATTRIBUTION; CAUSALITY ASSESSMENT TOOL; DECISION MAKING; DRUG SURVEILLANCE PROGRAM; GENETIC ALGORITHM; HUMAN; MEDICAL EXPERT; PROBABILITY; REVIEW; SIDE EFFECT;

EID: 84922688315     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2015.01.010     Document Type: Review

References (55)

1. World Health Organization causality assessment method. Available at < http://www.who-umc.org/defs.html> (accessed on 24.02.13).
2. Agbabiaka, T.B., Savović, J., Ernst, E., Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 31:1 (2008), 21–37.
3. Arimone, Y., Begaud, B., Miremont-Salame, G., Fourrier-Reglat, A., Moore, N., et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur. J. Clin. Pharmacol. 61 (2005), 169–173.
4. Arimone, Y., Miremont-Salamé, G., Haramburu, F., Molimard, M., Moore, N., Fourrier-Réglat, A., Bégaud, B., Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br. J. Clin. Pharmacol. 64:4 (2007), 482–488.
5. Arimone, Y., Bidault, I., Collignon, A.E., Dutertre, J.P., Gerardin, M., et al. Updating of the French causality assessment method. Fundament. Clin. Pharmacol., 6, 2010, 29.
6. Aronson, J.K., Ferner, R.E., Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327:7425 (2003), 1222–1225.
7. Avery, A.J., Anderson, C., Bond, C.M., Fortnum, H., Gifford, A., Hannaford, P.C., Hazell, L., Krska, J., Lee, A.J., McLernon, D.J., Murphy, E., Shakir, S., Watson, M.C., Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol. Assess. 15 (2011), 1–234.
8. Avner, M., Finkelstein, Y., Hackam, D., Koren, G., Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Paediatr. Drugs 9 (2007), 267–270.
9. Bates, D.W., Evans, R.S., Murff, H., Stetson, P.D., Pizziferri, L., Hripcsak, G., Detecting adverse events using information technology. J. Am. Med. Inform. Assoc. 10:2 (2003), 115–128.
10. Begaud, B., Standardized assessment of adverse drug reactions: the method used in France Special workshop—Clinical. Drug Inf. J. 18:3–4 (1984), 275–281.
11. Burns, L.C., Orsini, L., L'italien, G., Value-based assessment of Pharmacodiagnostic testing from early stage development to real-world use. Value Health 16:6 Suppl (2013), S16–S19 doi: http://dx.doi.org/10.1016/j.jval.2013.06.007. PubMed PMID: 24034307.
12. CDSCO Compensation in case of injury/death during a clinical trial. Available from: < http://www.cdsco.nic.in/GSR%2053(E)%20dated%2030.01.2013.pdf> (Last accessed on 2013 Feb 1).
13. Chien, J.Y., Ho, R.J., Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J. Pharm. Sci. 100 (2011), 53–58.
14. Clavenna, A., Bonati, M., Adverse drug reactions in childhood: a review of prospective studies and safety alerts. Arch. Dis. Child. 94 (2009), 724–728.
15. Cotrutz, C., Xing, L., Segment-based dose optimization using a genetic algorithm. Phys. Med. Biol. 48 (2003), 2987–2998.
16. Curtin, F., Schulz, P., Assessing the benefit: risk ratio of a drug—randomized and naturalistic evidence. Dialog. Clin. Neurosci. 13 (2011), 183–190.
17. Daly, A.K., Pharmacogenetics and human genetic polymorphisms. Biochem. J. 429 (2010), 435–449.
18. Daly, A.K., Using genome-wide association studies to identify genes important in serious adverse drug reactions. Ann. Rev., Pharmacol. Toxicol., 52(21), 2012, 35.
19. Davies, E.C., Green, C.F., Taylor, S., Williamson, P.R., Mottram, D.R., Pirmohamed, M., Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE, 4(2), 2009, e4439, 10.1371/journal.pone.0004439.
20. Davies, E.C., Rowe, P.H., James, S., et al. An investigation of disagreement in causality assessment of adverse drug reactions. Pharmaceut. Med. 25:1 (2011), 17–24.
21. de Vries, E.N., Ramrattan, M.A., Smorenburg, S.M., Gouma, D.J., Boermeester, M.A., The incidence and nature of in-hospital adverse events: a systematic review. Qual. Saf. Health Care 17:3 (2008), 216–223.
22. Dennis, F.T., Randall, P.S., Identification and reduction of adverse. J. Healthcare Leadership 2 (2010), 43–48 http://dx.doi.org/10.2147/JHL.S8022.
23. Doherty, M.J., Algorithms for assessing the probability of an adverse drug reaction. Respirat. Med. CME 2 (2009), 63–67.
24. Du, W., Tutag Lehr, V., Lieh-Lai, M., Koo, W., Ward, R.M., Rieder, M.J., et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J. Clin. Pharmacol., 2012 (Epub ahead of print).
25. Gallagher, R.M., Kirkham, J.J., Mason, J.R., et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE, 6(12), 2011, e28096, 10.1371/journal.pone.0028096.
26. Gallagher, R.M., Mason, J.R., Bird, K.A., Kirkham, J.J., Peak, M., Williamson, P.R., Nunn, A.J., Turner, M.A., Pirmohamed, M., Smyth, R.L., Adverse drug reactions causing admission to a pediatric hospital. PLoS ONE, 7(12), 2012, e50127, 10.1371/journal.pone.0050127.
27. Garcia-Cortes, M., Lucena, M.I., Pachkoria, K., Borraz, Y., Hidalgo, R., et al. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 27 (2008), 780–789.
28. Hauben, M., Bate, A., Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 14:7–8 (2009), 343–357, 10.1016/j.drudis.2008.12.012.
29. Heckerling, P., Canaris, G., Flach, S., Tape, T., Wigton, R., Gerber, B., Predictors of urinary tract infection based on artificial neural networks and genetic algorithms. Int. J. Med. Inf. 76 (2007), 289–296.
30. Jones, J.K., 2005. Determining causation from case reports. Pharmacoepidemiology. In: Strom, B.L. (Ed.), J. Wiley: Chichester, England, 2005.
31. Karch, F.E., Lasagna, L., Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther. 21:3 (1977), 247–254.
32. Khan, L.M., Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay – a systematic review. Eur. J. Clin. Pharmacol. 69 (2013), 1985–1996.
33. Khan, L.M., Al-Harthi, S.E., Saadah, O.I., et al. Impact of Pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital. Saudi Med. J. 33:8 (2012), 863–868.
34. Khan, L.M., Al-Harthi, S.E., Saadah, O.I., Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of Pharmacovigilance in reporting ADR. Saudi Pharmac. J. 21 (2013), 261–266.
35. Koh, Y., Li, S.C., A new algorithm to identify the causality of adverse drug reactions. Drug Saf. 28 (2005), 1159–1161.
36. Koh, Y., Yap, C.W., Li, S.C., A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int. J. Med. Informatics 77:6 (2008), 421–430.
37. Kramer, M.S., Leventhal, J.M., Hutchinson, T.A., Feinstein, A.R., Algorithm for the operational assessment of adverse drug reactions, I: background, description, and instructions for use. JAMA 242:7 (1979), 623–632.
38. Kulkarni, A., Bhatt, A., Causality assessment: a casualty of compensation?. Perspect. Clin. Res. 4:4 (2013 Oct), 196–198, 10.4103/2229-3485.120166.
39. Macedo, A.F., Marques, F.B., Ribeiro, C.F., Teixeira, F., Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J. Clin. Pharm. Ther. 28 (2003), 137–143.
40. Macedo, A.F., Marques, F.B., Ribeiro, C.F., Teixeira, F., Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol. Drug Saf. 14:12 (2005), 885–890.
41. Miremont, G., Haramburu, F., B́egaud, B., Ṕeŕe, J.C., Dangoumau, J., Adverse drug reactions: physicians’ opinions versus a causality assessment method. Eur. J. Clin. Pharmacol. 46:4 (1994), 285–289.
42. Nakamura, Y., Pharmacogenomics and drug toxicity. N. Engl. J. Med. 359 (2008), 856–858.
43. Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30 (1981), 239–245.
44. Park, M.Y., Yoon, D., Lee, K., Kang, S.Y., Park, I., Lee, S.H., et al. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database. Pharmacoepidemiol. Drug Saf. 20:6 (2011), 598–607 doi: 10.1002/pds.2139.
45. Peter Ian Pillans, Clinical perspectives in drug safety and adverse drug reactions. Expert Rev. Clin. Pharmacol. 1:5 (2008), 695–705.
46. Shapiro, S., Clinical judgment, common sense and adverse reaction reporting. Pharmacoepidemiol. Drug Saf. 13 (2004), 511–513.
47. Smyth, R.M., Gargon, E., Kirkham, J., Cresswell, L., et al. Adverse drug reactions in children—a systematic review. PLoS ONE, 3, 2012, e24061.
48. Strom, B.L., Kimmel, S.E., Textbook of Pharmacoepidemiology. 2006, John Wiley & Sons, Chichester, West Sussex; Hoboken, NJ pp. 168–169.
49. Talbot, J., Aronson, J.K., 2012. Causality algorithms. Stephens’ detection and evaluation of adverse drug reactions: principles and practice, sixth ed., John Wiley & Sons Ltd., UK, 2012, pp. 65–68.
50. Théophile, H., Arimone, Y., Miremont-Salamé, G., Moore, N., Fourrier-Réglat, A., Haramburu, F., Bégaud, B., Comparison of three methods (consensual expert judgment, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French Pharmacovigilance center. Drug Saf. 33:11 (2010), 1045–1054, 10.2165/11537780 Pub Med PMID: 20925441.
51. Théophile, H., André, M., Miremont-Salamé, G., Arimone, Y., Bégaud, B., Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine Pharmacovigilance case reports using consensual expert judgment as reference. Drug Saf. 36:10 (2013), 1033–1044, 10.1007/s40264-013-0083-1 Pub Med PMID: 23828659.
52. USFDA Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies. < http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf> (last accessed on 11.12.13).
53. Waller, P., Heeley, E., Moseley, J., Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf. 28 (2005), 843–850.
54. Weiss, J., Krebs, S., Hoffmann, C., et al. Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics 110 (2002), 254–257.
55. Wester, K., Jonnson, A.K., Sigset, O., Druid, H., Hagg, S., Incidence of fatal adverse drug reactions: a population based study. Br. J. Clin. Pharmacol. 65 (2008), 573–579.